Pharmaceuticals
PE firm Advent in talks to buy inVentiv for nearly $4 bn
01 Aug 2016
Advent has so far prevailed over rival buyout firm CVC Capital Partners in bidding for inVentiv, one of the largest pharmaceutical contract research organisations in the US